ProCE Banner Activity

Immunotherapy-Based Combinations in Intermediate HCC

Slideset

Slides from a live ASCO 2024 live satellite symposium covering the recent developments in the rapidly evolving landscape of intermediate HCC, including individualizing therapy based on Barcelona Clinic Liver Cancer staging, recent trial updates for TACE plus systemic therapy with durvalumab and bevacizumab, and other expert considerations relevant to interventional radiology practice.

Released: May 29, 2024

Expiration: May 28, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca